Fentanyl Transdermal Patch and Fosnetupitant: Interaction Details
- Fentanyl Transdermal Patch
- DuragesicAbstralSubsys +3 more
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Fentanyl Transdermal Patch and Fosnetupitant interaction:
Fosnetupitant
We don't have a separate drug information page for Fosnetupitant. The FDA's drug directory lists it as part of Akynzeo (fosnetupitant and palonosetron hydrochloride). Read the Fosnetupitant / Palonosetron drug information page → Have a question about Fosnetupitant? Ask a pharmacist, free →
Fentanyl Transdermal Patch
- Duragesic
- Abstral
- Subsys
- Ionsys
- Actiq
- Fentora
What Happens When You Take Fentanyl Transdermal Patch With Fosnetupitant
What can happen when they are taken together (rated Major)
Increased exposure of
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Netupitant and its fosnetupitant act as moderate of CYP3A4, so CYP3A4 substrates should not be used together with either agent for a period of 1 week. Giving a CYP3A4 substrate alongside netupitant or fosnetupitant can raise exposure to that substrate.
In a study, coadministering netupitant raised both the mean and the mean of erythromycin, a CYP3A4 substrate. For dexAMETHasone, a CYP3A4 probe substrate, the higher AUC persisted for as long as 8 days after a single netupitant dose.
For this reason, CYP3A4 substrates should be avoided for 1 week after netupitant. When a CYP3A4 substrate has to be given within that 1 week window, a lower dose of the substrate should be considered.1
The Fentanyl Transdermal Patch and Fosnetupitant Interaction, Explained
Fosnetupitant is given by IV to prevent nausea and vomiting from chemotherapy. Your body turns it into netupitant, which slows down an enzyme () that helps clear fentanyl. With less clearing, fentanyl from the patch can build up, which may cause extra drowsiness, slowed breathing, or confusion.
The effect can last about a week after a dose. The data behind this is mostly based on how the drug behaves in studies, not on reported patient harm. Please don't change or remove your patch on your own. Tell your pharmacist or doctor about both medicines, and your care team can adjust the dose and watch you closely.
Mechanism: Fosnetupitant is a of netupitant, a moderate . Fentanyl is a CYP3A4 , so may raise fentanyl exposure (, ) and increase effects, including and . Fentanyl itself is active, not a prodrug.
- Onset: rapid; CYP3A4 inhibition persists up to about 8 days after a single netupitant dose (dexamethasone AUC data).
- Evidence: theoretical for this pair, extrapolated from erythromycin and dexamethasone PK studies. Transdermal fentanyl has a prolonged, depot-driven kinetic profile.
- Management: avoid the combination for 1 week if possible. If necessary, consider reducing the fentanyl dose and monitor for sedation and respiratory depression.
See the 1 reference behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Fentanyl Transdermal Patch and Fosnetupitant Interact
The likely mechanism
of -mediated by netupitant
How to Manage the Fentanyl Transdermal Patch and Fosnetupitant Interaction
Your care team may try to avoid using these two together for about a week after fosnetupitant. If both are needed, the fentanyl dose may need to be adjusted and individualized by your care team, and your team may monitor you more closely.
- Keep using your patch exactly as prescribed unless told otherwise.
- Tell your pharmacist and oncology team that you use a fentanyl patch before chemotherapy.
- Report unusual sleepiness, confusion, or slow or shallow breathing right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Fentanyl Transdermal Patch or Fosnetupitant need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
2 reports from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Prescribing information: AKYNZEO oral capsules, netupitant palonosetron oral capsules
One study evaluated how long lasted by using dexAMETHasone as a CYP3A4 probe . Participants received dexAMETHasone 12 mg on day 1, followed by 8 mg on days 2, 3, 4, 6, 8, and 10, and were given a single dose of the combination netupitant 300 mg/palonosetron 0.5 mg on day 1. The mean of dexAMETHasone rose 1.6-fold on day 1, 2.4-fold on day 4, 1.5-fold on day 6, and 1.2-fold on day 8.1
-
Report 2 · Study title
Prescribing information: AKYNZEO oral capsules, netupitant palonosetron oral capsules
In a study, of erythromycin 500 mg with netupitant 300 mg raised the mean of erythromycin by 56% and its by 92%.1
Fentanyl Transdermal Patch and Fosnetupitant: Common Questions
How serious is the Fentanyl Transdermal Patch and Fosnetupitant interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Fentanyl Transdermal Patch and Fosnetupitant interaction managed?
Your care team may try to avoid using these two together for about a week after fosnetupitant. If both are needed, the fentanyl dose may need to be adjusted and individualized by your care team, and your team may monitor you more closely. Keep using your patch exactly as prescribed unless told otherwise. Tell your pharmacist and oncology team that you use a fentanyl patch before chemotherapy. Repo… Management is individual — always follow your own care team's guidance.
How quickly could this interaction happen?
The documented onset is "rapid". Effects can appear quickly, often within about 24 hours of combining the drugs.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
Ask About the Fentanyl Transdermal Patch and Fosnetupitant Interaction
Ask in your own words about taking Fentanyl Transdermal Patch and Fosnetupitant together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (1)
- Product Information: AKYNZEO(R) oral capsules, netupitant palonosetron oral capsules. Helsinn Therapeutics (US), Inc (per FDA), Iselin, NJ, 2018. DailyMed
Other Serious Interactions of Fentanyl Transdermal Patch and Fosnetupitant
Also serious with Fosnetupitant
Also serious with Fentanyl Transdermal Patch
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs. This interaction.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.